Trials / Completed
CompletedNCT02496117
Renal Nerves Stimulation Study
Feasibility of Electrical Mapping and Stimulation of Renal Arteries in Patients Undergoing Renal Denervation
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 56 (actual)
- Sponsor
- Diagram B.V. · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Study design: Investigator initiated, single centre, feasibility study Main objectives are twofold: 1. To investigate the feasibility of RNS in patients with therapy resistant hypertension, which is assessing the functional distribution of renal nerves using 3D imaging and differential pacing modalities. 2. To investigate the blood pressure responses and cardiac excitable properties to RNS, and subsequently perform a RDN procedure, guided by 3D mapping by two different techniques e.g. RNS-checked RDN and RNS-guided RDN procedures. Study population: 40 patients (18 - 80 yr old)
Detailed description
Background: Approximately 10-15% of adults with hypertension are considered to be treatment resistant because their hypertension is uncontrolled despite taking three or more drugs that includes a diuretic. Renal denervation (RDN) is a novel treatment option for therapy resistant hypertension and its rationale originates in denervating the renal sympathetic efferent and afferent coupling with the central autonomic nervous system. By denervating the renal arteries, general sympathetic tone is reduced. Currently, RDN is performed by placing in a spiral pattern 5-6 ablation lesions in each renal artery. 15-30% of the patients do not have any benefit from this procedure. The reason for this is unknown. Experimental data show that renal nerve stimulation (RNS) may serve as a functional endpoint to assess completeness of the RDN procedure. A RNS-guided RDN may prove to be superior to standard RDN (RNS-checked) in blood pressure control. Main objectives are twofold: 1. To investigate the feasibility of RNS in patients with therapy resistant hypertension, which is assessing the functional distribution of renal nerves using 3D imaging and differential pacing modalities. 2. To investigate the blood pressure responses and cardiac excitable properties to RNS, and subsequently perform a RDN procedure, guided by 3D mapping by two different techniques e.g. RNS-checked RDN and RNS-guided RDN procedures. Secondary objective: The secondary objective is to compare both techniques (RNS-checked vs. RNS-guided) in terms of efficacy and safety. Hypotheses: * We hypothesize that identification and localization of the sympathetic nerve bundles using 3D navigation systems and selective pacing manoeuvres will allow a functional approach to denervate the kidneys and improve the success rate of this procedure in patients with hypertension. * We hypothesize that the RNS-guided RDN procedure will show better blood pressure data during follow up, since the completeness has been assessed in contrast to the RNS-checked RDN procedure. Study design: Investigator initiated, single centre, prospective, feasibility study Study population: 40 patients (18 - 80 yr old) * 20 patients treated with RNS-checked RDN * 20 patients treated with RNS-guided RDN Intervention: Two different techniques will be used in this trial: 1. RNS-checked RDN 2. RNS-guided RDN Main study endpoints: Main study parameter will be the arterial blood pressure response to RNS prior to RDN and absence of blood pressure rise in response to pacing in the renal artery after RDN. Secondary study endpoints: Blood pressure at 3, 6, 12 months after the intervention, and change in blood pressure compared to measurement before the intervention.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Electrical mapping, nerve stimulation checked renal denervation procedure | |
| PROCEDURE | Electrial mapping, nerve stimulation guided renal denervation procedure |
Timeline
- Start date
- 2014-03-14
- Primary completion
- 2019-07-04
- Completion
- 2019-07-04
- First posted
- 2015-07-14
- Last updated
- 2020-05-06
Locations
1 site across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT02496117. Inclusion in this directory is not an endorsement.